US tech company unveils sterlite device that uses magnetic field to block viruses

By LIZ WALLACE SAN FRANCISCO, Calif.

— The latest invention in the fight against infections is a product called sterlite that uses a magnetic field in order to trap viruses.

The idea is to help people get rid of germs faster by blocking them from reaching the skin, according to the company that developed it, Medtronic.

“If you have a virus in your body, you want to keep it from spreading,” said Dr. Mark Eppley, vice president for the clinical and clinical development at Medtrol, a biotechnology company based in Arlington, Va.

“But you want the virus to spread as much as possible to as many people as possible.

So if you block the viral particles, they don’t get to you, they go to the lungs.

And that is not the case for germs.

This enzyme-magnetic polymer is the key to sterlite’s effectiveness. “

So we’ve created an enzyme-based polymer called sterlium that is magnetic in nature, and it can trap viruses in a magnetic material.”

This enzyme-magnetic polymer is the key to sterlite’s effectiveness.

Medtronics product, called Medtroglide, is a two-part polymer made of two strands of sterlized metal, one of which is attached to the skin.

The other strand is attached in a fashion similar to a zipper.

“What this is about is this enzyme is the magnetizing component of the product, and the magnetic field allows it to trap the virus in a non-magnetizing way,” said Epply.

“That’s a new type of enzyme-like enzyme that allows you to trap virus in the body without it getting in the way.”

Medtronics’ product, Medtlabs, is designed to be applied to the scalp and the scalp-hair barrier, both of which are used to trap germs and other infectious organisms in the environment.

“We’re actually creating an enzyme that is able to trap an infectious virus in an enzyme,” said Matt Schmitt, vice-president of medical and clinical product development at the company.

“It’s like a zipper on the skin.”

The product was first announced in March, and its use is set to be the first to be used in patients.

“The product is designed for use in people with or without a specific disease, and we’re looking to move it to the marketplace in the near future,” said Schmitt.

Medtlamp is a unique product that uses an enzyme called the pheromone receptor (PRR), which detects and detects the chemical compounds that are released by germs, and which are then used to control infection and prevent infection.

The PRR is the only enzyme that has been shown to block a range of viruses.

“This enzyme is able not only to block germs from getting to the surface of the skin but also to control infections, prevent disease progression and treat inflammation,” said Tom Visser, a senior vice president at Medtech Inc., a biotech company based at the University of Texas Medical Branch in Galveston, Tex.

“Medtrol’s products are the first products that are specifically designed to target a specific virus, and they are currently being tested for the efficacy of this enzyme.”

Schmitt explained that the product is a synthetic version of the enzyme used in many of the products that doctors use to treat infections.

“You can see this in many products today, and this enzyme has been around for a long time, and so this is a first step,” said Vissers.

“There are two important things about this enzyme.

One is that the enzyme works in both ways: it binds the virus, it does not bind the virus itself, and then it also binds the immune system.

The Medtropic team is also developing a third enzyme called a sterlase, which uses an enzymatic process to convert sterlite into a protein. “

Our goal is to get it into a drug pipeline and into the clinic,” he said.

The Medtropic team is also developing a third enzyme called a sterlase, which uses an enzymatic process to convert sterlite into a protein.

These are enzymes that can bind to different viruses and other viruses and viruses that are naturally found in the human body, and to be able to bind them we need to find the right virus and then we need the right protein.

“For now, we are working with a number of virus species, and one of the things we’re finding is that certain viruses are much more effective than others, so the sterlases will be able bind to the virus that has the most potential for success,” said Wanda Smith, vice chancellor of marketing for Medtech.

“As we move forward, we’re seeing an increased interest from pharmaceutical companies in developing enzymes that are designed to treat specific diseases, and a greater need for